Eckert & Ziegler SE (ETR: EUZ)

Germany flag Germany · Delayed Price · Currency is EUR
44.58
+0.18 (0.41%)
Dec 20, 2024, 5:35 PM CET
14.07%
Market Cap 929.29M
Revenue (ttm) 277.72M
Net Income (ttm) 29.39M
Shares Out 20.85M
EPS (ttm) 1.40
PE Ratio 25.96
Forward PE 24.94
Dividend 0.05 (0.11%)
Ex-Dividend Date Oct 3, 2024
Volume 38,678
Open 43.72
Previous Close 44.40
Day's Range 43.36 - 44.84
52-Week Range 32.74 - 50.05
Beta 1.30
Analysts n/a
Price Target n/a
Earnings Date Mar 27, 2025

About Eckert & Ziegler SE

Eckert & Ziegler SE manufactures and sells isotope technology components worldwide. It operates through two segments, Medical and Isotope Products. The company provides small implants for the treatment of prostate cancer seeds; and eye applicators based on ruthenium-106 and iodine-125 for the treatment of uveal melanomas; brain seed, HDR and brachytherapy; ophthalmological products; therapeutic and radiotherapy accessories, X-Ray therapy, GA-68 generators, radiochromatography, hot cells; and radiopharmaceuticals, laboratory equipment, radiosynt... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 2024
Employees 1,075
Stock Exchange Deutsche Börse Xetra
Ticker Symbol EUZ
Full Company Profile

Financial Performance

In 2023, Eckert & Ziegler SE's revenue was 246.09 million, an increase of 10.74% compared to the previous year's 222.23 million. Earnings were 26.30 million, a decrease of -10.17%.

Financial Statements

News

EQS-News: Eckert & Ziegler Submits GalliaPharm for Approval by Japan’s Health Authority MHLW

EQS-News: Eckert & Ziegler SE / Key word(s): Regulatory Admission/Market Launch Eckert & Ziegler Submits GalliaPharm for Approval by Japan’s Health Authority MHLW 13.12.2024 / 09:00 CET/CEST The issue...

8 days ago - Wallstreet:Online

EQS-News: Eckert & Ziegler and Ariceum Therapeutics Sign Global Supply Agreement for the Development of Next-Generation Radiotherapeutics for Precision Cancer Treatments

EQS-News: Eckert & Ziegler SE / Key word(s): Incoming Orders/Alliance Eckert & Ziegler and Ariceum Therapeutics Sign Global Supply Agreement for the Development of Next-Generation Radiotherapeutics fo...

16 days ago - Wallstreet:Online

EQS-News: Eckert & Ziegler Begins Production of Actinium-225, Paving the Way for GMP-Grade Supply

EQS-News: Eckert & Ziegler SE / Key word(s): Product Launch Eckert & Ziegler Begins Production of Actinium-225, Paving the Way for GMP-Grade Supply 02.12.2024 / 09:00 CET/CEST The issuer is solely res...

19 days ago - Wallstreet:Online

EQS-News: Eckert & Ziegler Achieves European Approval for Theralugand - Lutetium-177 Chloride (n.c.a)

EQS-News: Eckert & Ziegler SE / Key word(s): Regulatory Approval/Market Launch Eckert & Ziegler Achieves European Approval for Theralugand - Lutetium-177 Chloride (n.c.a) 27.11.2024 / 09:00 CET/CEST T...

24 days ago - Wallstreet:Online

Eckert & Ziegler Boosts Financial Year Forecast Again!

Eckert & Ziegler SE has boosted its 2024 financial outlook, anticipating higher sales and EBIT. This Berlin-based company, listed on TecDAX and SDAX, credits strong 9-month results for the revision. J...

4 weeks ago - Wallstreet:Online

EQS-Adhoc: Eckert & Ziegler raises its forecast for the current financial year once again

EQS-Ad-hoc: Eckert & Ziegler SE / Key word(s): Change in Forecast Eckert & Ziegler raises its forecast for the current financial year once again 22-Nov-2024 / 15:27 CET/CEST Disclosure of an inside in...

4 weeks ago - Wallstreet:Online

EQS-Adhoc: Eckert & Ziegler and Telix Pharmaceuticals Enter into a Collaboration and Licence Agreement for Actinium-225

EQS-Ad-hoc: Eckert & Ziegler SE / Key word(s): Alliance Eckert & Ziegler and Telix Pharmaceuticals Enter into a Collaboration and Licence Agreement for Actinium-225 13-Nov-2024 / 08:54 CET/CEST Disclo...

5 weeks ago - Wallstreet:Online

Eckert & Ziegler Boosts Sales & Earnings in First 9 Months of 2023

Eckert & Ziegler SE has shown robust growth in 2024, with significant increases in sales and earnings, reinforcing their optimistic forecast for the year. Full details will be unveiled on November 14....

2 months ago - Wallstreet:Online

EQS-Adhoc: Eckert & Ziegler Again Increases Sales and Earnings in the First Nine Months Compared to Previous Year

EQS-Ad-hoc: Eckert & Ziegler SE / Key word(s): 9 Month figures/Preliminary Results Eckert & Ziegler Again Increases Sales and Earnings in the First Nine Months Compared to Previous Year 15-Oct-2024 / ...

2 months ago - Wallstreet:Online

EQS-News: Eckert & Ziegler and GlyTherix Sign Agreement for Lutetium-177 Supply

EQS-News: Eckert & Ziegler SE / Key word(s): Contract/Alliance Eckert & Ziegler and GlyTherix Sign Agreement for Lutetium-177 Supply 08.10.2024 / 08:00 CET/CEST The issuer is solely responsible for th...

2 months ago - Wallstreet:Online

EQS-DD: Pentixapharm Holding AG: Dr. Hakim Bouterfa, Allocation of 3,800 spin-off shares in Pentixapharm Holding AG due to the ownership of 3,800 shares in Eckert & Ziegler SE.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 04.10.2024 / 11:30 CET/CEST The issuer is solely responsi...

2 months ago - Wallstreet:Online

EQS-DD: Pentixapharm Holding AG: Dr. Andreas Eckert, Allocation of 4 spin-off shares in Pentixapharm Holding AG due to the ownership of 4 shares in Eckert & Ziegler SE.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 04.10.2024 / 11:30 CET/CEST The issuer is solely responsi...

2 months ago - Wallstreet:Online

EQS-DD: Pentixapharm Holding AG: Dr. Harald Hasselmann, Allocation of 2,200 spin-off shares in Pentixapharm Holding AG due to the ownership of 2,200 shares in Eckert & Ziegler SE.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 04.10.2024 / 11:30 CET/CEST The issuer is solely responsi...

2 months ago - Wallstreet:Online

EQS-DD: Pentixapharm Holding AG: Jens Giltsch, Allocation of 761 spin-off shares in Pentixapharm Holding AG due to the ownership of 761 shares in Eckert & Ziegler SE.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 04.10.2024 / 11:30 CET/CEST The issuer is solely responsi...

2 months ago - Wallstreet:Online

EQS-News: Eckert & Ziegler: Spin-off of Pentixapharm AG Registered with the Commercial Register

EQS-News: Eckert & Ziegler SE / Key word(s): Miscellaneous Eckert & Ziegler: Spin-off of Pentixapharm AG Registered with the Commercial Register 02.10.2024 / 11:43 CET/CEST The issuer is solely respon...

2 months ago - Wallstreet:Online

EQS-News: Pentixapharm Holding AG, a Subsidiary of Eckert & Ziegler SE, Plans IPO on the Prime Standard of the Frankfurt Stock Exchange

EQS-News: Pentixapharm Holding AG / Key word(s): IPO Pentixapharm Holding AG, a Subsidiary of Eckert & Ziegler SE, Plans IPO on the Prime Standard of the Frankfurt Stock Exchange 12.09.2024 / 15:00 CE...

3 months ago - Wallstreet:Online

EQS-News: Eckert & Ziegler opens new facilities for radiopharmaceutical plant engineering in Dresden

EQS-News: Eckert & Ziegler SE / Key word(s): Expansion/Miscellaneous Eckert & Ziegler opens new facilities for radiopharmaceutical plant engineering in Dresden 20.08.2024 / 17:00 CET/CEST The issuer i...

4 months ago - Wallstreet:Online

EQS-News: Eckert & Ziegler becomes European contract manufacturer for Telix's innovative Phase III ProstACT GLOBAL study

EQS-News: Eckert & Ziegler SE / Key word(s): Contract/Alliance Eckert & Ziegler becomes European contract manufacturer for Telix's innovative Phase III ProstACT GLOBAL study 13.08.2024 / 09:00 CET/CES...

4 months ago - Wallstreet:Online

Eckert & Ziegler Sees Strong Sales and Earnings Surge in H1 2024

In the first half of 2024, our company saw remarkable growth, with sales surging by 23% to €145.4 million and net profit soaring by 65% to €18.0 million. The Medical and Isotope Products segments led ...

4 months ago - Wallstreet:Online

EQS-News: Eckert & Ziegler Continues Sales and Earnings Growth in the First Half of 2024

EQS-News: Eckert & Ziegler SE / Key word(s): Half Year Report/Quarter Results Eckert & Ziegler Continues Sales and Earnings Growth in the First Half of 2024 09.08.2024 / 07:45 CET/CEST The issuer is s...

4 months ago - Wallstreet:Online